VC-backed Translate Bio goes public
Lexington, Massachusetts-based Translate Bio Inc, a messenger RNA therapeutics company, has raised about $121.6 million for its IPO after pricing its 9.35 million shares at $13 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol "TBIO." Citigroup, Leerink Partners and Evercore ISI are the lead underwriters. Translate Bio's pre-IPO backers include M Ventures, SR One, Leerink Partners, Partners Innovation Fund and Rock Springs Capital, according to Crunchbase.
28 June 2018•2 mins read
